VIDRAFT Benchmarks LLMs on Real Drug Discovery for Malaria and TB
Korean AI research firm VIDRAFT has launched the Open Discovery Challenge, a public competition hosted on Hugging Face that tasks participants with using AI to propose drug candidates for malaria and tuberculosis. Submissions are scored against a multi-factor pharmacological pipeline covering efficacy, toxicity, target binding, ADME properties, and preclinical viability. The two diseases were chosen deliberately due to their outsized impact on low-income populations and the historically weak market incentives for private pharmaceutical research in these areas. The challenge drew over 2,000 candidate submissions within three days of launch. Early results show Claude-family models leading with a median score of 43.7 on the malaria season, outperforming OpenAI-family submissions by roughly 12 points and Gemini-family models by a significantly wider margin.
This is an AI-generated summary. ShortSingh links to the original source for the complete article.

Discussion (0)
Log in to join the discussion and vote.
Log in